Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyeChild 01: treating children with acute myeloid leukaemia
ISRCTN12389567Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Apr 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin, mitoxantrone, liposomal daunorubicin, cytarabine, fludarabine and 2 more in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Extramedullary leukemia (EML) (7 arms), sponsored by University of Birmingham. Primary endpoint: Incidence of dose limiting toxicities. Started Apr 2016; status: active, not recruiting.
02
Drugs
gemtuzumab ozogamicinmitoxantroneliposomal daunorubicincytarabinefludarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Extramedullary leukemia (EML)
Beyond the preview
Go deeper on ISRCTN12389567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12389567.